Issue Price
₹36
Per Share
GMP
NIL
Grey Market
Est. Listing
₹36
Expected Price
Min. Application
₹216,000
2 lots × 3000 shares
Incorporated in 2012, Ahmedabad-based Earum Pharmaceuticals Limited is engaged in trading, marketing, distribution of pharmaceutical formulation products. The company has 125 drugs formulation products including multivitamins, gynaecology drugs, steroids, anti-biotic drugs, cerebral activator drugs, gastrointestinal drugs, etc.The company is also involved in the trading business of active pharmaceutical ingredients (API's) including Amoxicillin Trihydrate IP, Levofloxacin Hemihydrate IP and Albendazole IP. Earum Pharmaceuticals is primarily engaged in two types of business activities; marketing of its own formulations products and trading of other brands' generic formulations. Currently, it has around 24 products which are manufactured by 3rd parties and marketed by the company under its brand name.It has a warehouse at Ahmedabad, Gujarat equipped with all amenities to process business operations smoothly. The company has a domestic and international presence across South East Asia, Latin America and Africa.Future goals of Earum Pharmaceuticals Ltd are:1. Make global presence more prominent2. Enhance customer satisfaction by improving market skills3. Deal in quality standard productsThe competitive strengths of the company are:1. Wide product range2. The experienced promoter of 11+ years experience3. Quality assurance
Earum Pharmaceuticals Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| Market Maker | 96,000 | — | ₹0.35 Cr | — |
| TOTAL | 1,848,000 | 100.00% | ₹6.65 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 3,000 | ₹108,000 |
| Retail (Max) | 13 | 39,000 | ₹1,404,000 |
| sNII (Min) | 14 | 42,000 | ₹1,512,000 |
| bNII (Min) | 68 | 204,000 | ₹7,344,000 |
| Particulars | 31-Dec-18 | 31-Mar-18 | 31-Dec-17 |
|---|---|---|---|
| Revenue from Operations | 3449.85 | 3543.67 | 2333.95 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 86.51 | 85.65 | 15.98 |
| Net Worth | N/A | N/A | N/A |
| Total Assets | 2741.00 | 2052.88 | 1108.45 |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | N/A | N/A | N/A |